A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study Status
Open to Enrollment
Study Description
This clinical trial is for men with metastatic castration-resistant prostate cancer (mCRPC). The purpose of the study is to evaluate the anti-tumor activity and safety of an experimental drug called PSMA ADC. The study will also evaluate how well men with mCRPC tolerate the drug.
PSMA ADC belongs to a class of medicines called antibody-drug conjugates. PSMA ADC is made up of three parts: an antibody; a drug that kills cancer cells; and a linker that holds to the first two parts together. The antibody in PSMA ADC recognizes a protein on the surface of prostate cancer cells, called “prostate-specific membrane antigen (PSMA),” and binds to it. Once bound, PSMA ADC enters the prostate cancer cell, and the cancer-killing drug portion is released into the cancer cells.
All study participants will receive PSMA ADC, which is administered via infusion. There is no placebo in this study. Participants will receive PSMA ADC every three weeks for up to eight doses.
Disease Status and/or Stage
Metastatic Castration-Resistant Prostate Cancer
Sponsor
PSMA Development Company
Key Eligibility
- Men age 18 and older
- Metastatic castration-resistant prostate cancer
- Prior treatment with at least one, but not more than two, cytotoxic chemotherapy regimens, one of which must have contained docetaxel
- Detailed eligibility reviewed when you contact the study team
Principal Investigator
Contact
- Renee Khan, RN
- (212) 746-1851
- [email protected]
Protocol ID
PSMA ADC 2301
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Erica Bersin
Tel: (646) 962-8232
[email protected]
